Welcome to our dedicated page for Alkermes news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes stock.
Alkermes plc develops and commercializes neuroscience medicines, with proprietary commercial products used in alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Company news commonly covers quarterly financial results, full-year expectations, commercial execution and presentations at healthcare and CNS investor conferences.
Clinical and medical updates focus on the company’s sleep-wake and psychiatric portfolio, including LYBALVI in schizophrenia and bipolar I disorder and alixorexton, an investigational oral selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. Other updates include peer-reviewed data publications, research award programs and corporate developments tied to Alkermes’ biopharmaceutical operations.
Acorda Therapeutics reported its Q3 2022 financial results, showing a net revenue increase for both INBRIJA and AMPYRA. INBRIJA U.S. sales reached $7.8 million, up 1% year-over-year, while AMPYRA revenue rose 5% to $21.1 million. The company secured a $16.5 million arbitration award from Alkermes, relieving it from royalty payments on AMPYRA. A special stockholders meeting is scheduled for November 4, 2022, to authorize a reverse stock split to avoid Nasdaq delisting. The 2022 guidance remains unchanged, with projected AMPYRA revenue between $68-78 million.
Alkermes plc (Nasdaq: ALKS) announced the recipients of the 2022 Alkermes Inspiration Grants, awarding funding to nine nonprofit organizations addressing addiction, serious mental illness, and cancer. The grants focus on historically under-resourced communities and received nearly 250 applications. Since 2016, the program has awarded over $4.5 million to support innovative health initiatives. CEO Richard Pops highlighted the potential impact of these programs for communities across the U.S.
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast on November 2, 2022, at 8:00 a.m. ET to discuss its third quarter financial results. The event will include updates from management regarding the company's performance. Interested parties can access the webcast through the Alkermes website and can dial in using the provided phone numbers. A replay will be available shortly after the event. Alkermes develops innovative medicines for neuroscience and oncology, with a focus on conditions such as alcohol and opioid dependence.
Acorda Therapeutics secured a favorable ruling from a three-judge arbitration panel against Alkermes PLC, with a monetary award of $15 million plus $1.5 million in pre-judgment interest. The decision relieves Acorda from paying royalties on AMPYRA sales, allowing them to source AMPYRA at competitive rates. This will enhance their profit margins and support ongoing services for patients with multiple sclerosis.
Alkermes plc (Nasdaq: ALKS) has opened applications for its 5th Annual Alkermes Pathways Research Awards, offering grants of up to $100,000 for early-career researchers focused on schizophrenia and bipolar disorder. The application period runs until Nov. 30, 2022. This initiative aims to support research addressing critical public health issues. Award recipients will be selected by an independent committee and have previously contributed to significant advancements in neuroscience. For eligibility details, visit www.PathwaysResearchAwards.com.
Alkermes plc (Nasdaq: ALKS) presented significant research findings at the Psych Congress from Sept. 17 to Sept. 20, aimed at advancing knowledge in serious mental illnesses, particularly schizophrenia and bipolar I disorder. Highlights included studies on Olanzapine/Samidorphan and long-acting injectables. Chief Medical Officer Craig Hopkinson emphasized the company's dedication to mental health research, looking forward to ongoing collaborations. Alkermes maintains a strong focus on developing innovative treatments for mental health disorders.
Alkermes plc (Nasdaq: ALKS) reported second-quarter 2022 revenues of $276.2 million, down from $303.7 million year-over-year. Proprietary product net sales increased to $190.8 million, driven by VIVITROL and ARISTADA. However, GAAP loss per share was $0.18, compared to a gain of $0.01 in the prior year. The company raised its full-year revenue expectations to $1,050 - $1,120 million, largely due to the successful launch of LYBALVI. Operating expenses rose to $310.7 million, reflecting increased investments.
Alkermes plc (Nasdaq: ALKS) will host a conference call on July 27, 2022 at 8:00 a.m. ET to discuss its second quarter financial results and provide updates on company progress. Interested parties can access the webcast via Alkermes' website, with a replay available two hours post-event. Alkermes focuses on developing medicines in neuroscience and oncology, with a portfolio addressing conditions such as alcohol and opioid dependence, schizophrenia, and bipolar I disorder.
Alkermes plc (Nasdaq: ALKS) reported the results of its 2022 Annual General Meeting held on July 7, 2022. All four nominees for the Board of Directors were re-elected with over 97% of shareholder votes. Additionally, the advisory vote on executive officer compensation passed with over 86% approval. Lead Independent Director Nancy J. Wysenski emphasized the strong support for the Board's refreshment efforts, highlighting the company's focus on strategic priorities and operational execution aimed at driving growth and shareholder value. Full vote results will be disclosed via SEC filing.
Sarissa Capital Management expresses concern over the influence of CEO Richard Pops on Alkermes' board. Despite Alkermes' revenues exceeding $1 billion, they report consistent net losses and a nearly 60% stock price drop over five years, underperforming the IBB by 130%. Sarissa supports newly appointed directors and plans to vote for their slate at the upcoming annual meeting. If a Sarissa representative is not appointed soon, they may pursue action under Irish law to replace certain board members to act in shareholders' best interests.